Cargando…
Chronic lymphocytic leukaemia—what is new and notable in 2021, with a special focus on COVID-19
In the last few years, treatment of patients exhibiting chronic lymphocytic leukaemia has changed extensively due to advances in the development of targeted therapies. The role of immunochemotherapy has been for the most part replace and the guidelines have been modified accordingly. Herein, we give...
Autores principales: | Prochazka, Katharina T., Neumeister, Peter |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Vienna
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8356209/ https://www.ncbi.nlm.nih.gov/pubmed/34394761 http://dx.doi.org/10.1007/s12254-021-00735-z |
Ejemplares similares
-
What’s new and notable in bacterial spore killing!
por: Setlow, Peter, et al.
Publicado: (2021) -
Knowledge Representation and Management: Notable Contributions in 2021
por: Cui, Licong, et al.
Publicado: (2022) -
Will New Drugs Replace Transplants for Chronic Lymphocytic Leukaemia?
por: Yang, Shenmiao, et al.
Publicado: (2021) -
COVID-19 in a patient with chronic lymphocytic leukaemia
por: Jin, Xiang-Hong, et al.
Publicado: (2020) -
The Seventeenth International Congress of Medicine: Notabilities and Notable Items
Publicado: (1913)